Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
31 May 2007Website:
http://amicusrx.comNext earnings report:
08 November 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Fri, 27 Sep 2024 23:48:26 GMTDividend
Analysts recommendations
Institutional Ownership
FOLD Latest News
Amicus Therapeutics is making steady progress towards promised profitability, driven by the continued growth of Galafold and the launch of Pombiliti+Opfolda. The "beat-and-raise" guidance profile is missing this year and could partially explain the lack of the year-to-date share price momentum. Pombiliti+Opfolda's launch is progressing well, with patients switching from both Nexviazyme and Lumizyme.
PRINCETON, N.J., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in upcoming presentations at the following investor conferences in September.
PRINCETON, N.J., Aug. 30, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in upcoming presentations at the following investor conferences in September.
Amicus' (FOLD) lead drug, Galafold, is witnessing solid sales uptake so far. The approval for Pombiliti + Opfolda also aids sales.
Amicus Therapeutics focuses on rare diseases like Fabry and Pompe, with Galafold and Pombiliti as main value drivers. Galafold is the only oral treatment for Fabry disease, stabilizing the alpha-Gal A enzyme and capturing significant market share. Pombiliti, combined with Opfolda, treats late-onset Pompe disease, showing strong adoption and receiving multiple awards for its efficacy.
Amicus (FOLD) rises 13% as it reports second-quarter 2024 results, wherein both earnings and sales beat the Zacks Consensus Estimate. The company updates its financial guidance for 2024.
Amicus Therapeutics (FOLD) came out with quarterly earnings of $0.06 per share, beating the Zacks Consensus Estimate of $0.03 per share. This compares to loss of $0.15 per share a year ago.
Corner Post, Inc. v. Board of Governors of the Federal Reserve System Corner Post, Inc. v. Board of Governors of the Federal Reserve System
National Association of Private Fund Managers, et al. v. Securities and Exchange Commission National Association of Private Fund Managers, et al. v. Securities and Exchange Commission
Despite experiencing a drop in share price to below $10, Amicus Therapeutics has shown strong revenue growth. Its products, Galafold and Pombiliti + Opfolda, have promising sales potential and are gaining traction in the market. Analysts are also optimistic about the company's future.
- 1(current)
- 2
What type of business is Amicus Therapeutics?
Amicus Therapeutics, Inc. is a global biotechnology company dedicated to the discovery, development, and delivery of medicines for the treatment of rare diseases. Amicus Therapeutics, Inc. was registered in 2002, with its headquarters located in Philadelphia, Pennsylvania. The company's main product is Galafold, the first approved oral precision medicine for people living with Fabry disease and having genetically amenable variants. The drug is approved under the trade name Galafold in the United States, European Union, United Kingdom, and Japan, with several additional approvals and applications under review in multiple regions worldwide.
What sector is Amicus Therapeutics in?
Amicus Therapeutics is in the Healthcare sector
What industry is Amicus Therapeutics in?
Amicus Therapeutics is in the Biotechnology industry
What country is Amicus Therapeutics from?
Amicus Therapeutics is headquartered in United States
When did Amicus Therapeutics go public?
Amicus Therapeutics initial public offering (IPO) was on 31 May 2007
What is Amicus Therapeutics website?
https://amicusrx.com
Is Amicus Therapeutics in the S&P 500?
No, Amicus Therapeutics is not included in the S&P 500 index
Is Amicus Therapeutics in the NASDAQ 100?
No, Amicus Therapeutics is not included in the NASDAQ 100 index
Is Amicus Therapeutics in the Dow Jones?
No, Amicus Therapeutics is not included in the Dow Jones index
When was Amicus Therapeutics the previous earnings report?
No data
When does Amicus Therapeutics earnings report?
The next expected earnings date for Amicus Therapeutics is 08 November 2024